Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Selecting Treatment for Relapsed/Refractory Multiple Myeloma in the Era of Multiple Choices

JHOP - December 2019 Vol 9, No 4 - Multiple Myeloma
Download PDF
Meg Barbor, MPH

Keeping up with the many treatment advances in relapsed or refractory multiple myeloma can be a challenge for even the most informed providers, according to Jorge J. Castillo, MD, Clinical Director, Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.

“In myeloma, a higher variety of medications have been approved in recent years than in any other oncology malignancy,” Dr Castillo said at the NCCN 2019 Hematologic Malignancies meeting. “And that, in itself, is a good thing. But then it also gives us a number of headaches.”

The main headache, he says, is simply deciding which treatment options to use for which patient. The NCCN guidelines for multiple myeloma list 8 preferred regimens alone, in addition to more than 20 recommended regimens. Choice of treatment comes down to personalization, according to Dr Castillo.

Treatment Selection

Disease-related factors. Deciding on a course of treatment for relapsed or refractory multiple myeloma often seems less scientific and more of a “wheel of fortune,” he said. To hone this process, first consider an individual’s disease-related factors, such as the nature of relapse (indolent vs aggressive), risk stratification (high, intermediate, or low), genomic abnormalities, and disease burden.

Patient-related factors should also be carefully weighed, especially patient preferences (intravenous vs oral therapy, distance to treatment center) and clinical considerations, such as renal insufficiency. Almost 50% of all patients with multiple myeloma will have some degree of renal insufficiency; in these patients, providers should favor cyclophosphamide, proteasome inhibitors, and dose-reduced immunomodulatory drugs (IMiDs), because these are more likely to be effective, but with lower toxicity than other drugs.

“In the relapsed and refractory setting, patient preference has become much more important,” Dr Castillo noted.

Previous therapy is also a critical factor that should inform treatment decisions. Consider whether the patient progressed while receiving proteasome inhibitors or IMiDs, and if they progressed on or off maintenance. What was the depth and duration of their response?

Treatment toxicity and patient comorbidities should also be considered. Speaking in general terms, Dr Castillo warns clinicians to be wary of using bortezomib and thalidomide in patients with preexisting neuropathy, carfilzomib in patients with cardiac issues and in elderly patients, daratumumab in patients with pulmonary issues, and IMiDs in those with thrombotic episodes.

Although these drugs are not contraindicated, knowing which treatments may result in worse outcomes in certain populations can help to narrow down the options.

“Every intervention that we have will be related to some toxicity,” he said. “So, we need to make sure that the benefit we provide to our patients is higher than the potential toxicity.”

Triplet Therapy After Relapse

Combination treatment with lenalidomide and dexamethasone has extended survival and time to progression in relapsed or refractory multiple myeloma. However, “triplets are the way to go, not only for frontline disease, but also for relapsed disease,” Dr Castillo says.

Many studies have explored triplet therapy in patients with relapsed or refractory disease who had minimal (≤20%) previous exposure to lenalidomide. In these studies, adding carfilzomib to a lenalidomide-dexamethasone regimen showed promising efficacy after first relapse, as did adding the oral proteasome inhibitor ixazomib to the lenalidomide-dexamethasone regimen in the relapsed or refractory setting.

Daratumumab added to a lenalidomide-dexamethasone regimen has dem­onstrated significant improvements in progression-free survival (PFS), and elotuzumab, when added to the combination therapy in patients with minimal lenalidomide exposure, has also shown promising efficacy.

However, Dr Castillo warned that the applicability of these findings is limited, because many patients in clinical practice will have had higher exposure to lenalidomide. In patients with previous lenalidomide exposure, adding carfilzomib to dexamethasone led to a ­“remarkable” PFS benefit versus the combination of bortezomib-dexamethasone. In addition, evidence has shown that adding daratumumab to bortezomib-dexamethasone was superior to bortezomib-dexamethasone alone.

Dr Castillo added that certain toxicity trends should also serve to guide treatment. For example, neuropathy is often more common in patients using proteasome inhibitors; infections are more common with daratumumab combinations, and cardiotoxicity is more prominent with carfilzomib therapy. Certain side effects, such as diarrhea, occur across the board.

For patients in second relapse or later, “pomalidomide-based regimens are an important resource,” but providers should remain vigilant about the risk of neuropathy, Dr Castillo advises.

Primary Refractory Disease

Clinical trials have yet to be designed solely for patients with primary refractory disease. “We don’t have clinical data supporting specific approaches in this type of patient, besides getting them to transplant early and using a triplet or even a quadruplet as data accumulate,” Dr Castillo said. He listed recommendations to guide the treatment of these patients:

  1. First, autologous stem-cell transplant (ASCT) should be standard in transplant-eligible patients with relapsed disease after primary therapy that did not include ASCT.
  2. A second ASCT should be considered for patients relapsing after primary therapy that included ASCT with initial remission after 18 months.
  3. Finally, allogeneic stem-cell transplantation should be considered in patients with high-risk disease and early (<24 months) disease relapse after primary therapy that included ASCT.

General Rules of Thumb

Dr Castillo also listed a few general rules of thumb:

  1. Consider nonlenalidomide triplets in patients whose disease progressed during lenalidomide maintenance, but a lenalidomide-based triplet is advised in those patients who had a prolonged PFS after lenalidomide-based induction.
  2. Consider a triplet with different novel agents in patients with primary refractory disease.
  3. Always consider referring for transplant if no ASCT was performed during induction.
    According to Dr Castillo, current research in multiple myeloma is focusing on CAR (chimeric antigen receptor) T-cell therapies, antibody-drug conjugates, and bispecific T-cell engagers, and these emerging treatments should be on all providers’ radar.

Related Items
Biosimilars Are Key Components of Oncology Today: Brush Up on the Basics
Meg Barbor, MPH
JHOP - December 2019 Vol 9, No 4 published on December 13, 2019 in NCCN News
What Is the Role of Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukemia?
Meg Barbor, MPH
JHOP - December 2019 Vol 9, No 4 published on December 13, 2019 in Leukemia, NCCN News
Formal Hereditary Cancer Genetics Counseling Improves Patient Outcomes
Meg Barbor, MPH
Web Exclusives published on November 7, 2019 in Genetic Counseling
Oral Cancer and Sex in the Era of HPV Infection
Meg Barbor, MPH
Web Exclusives published on October 28, 2019 in Head and Neck Cancer
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Updates, In the News, Multiple Myeloma, Pediatric Cancer
FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma
Web Exclusives published on September 30, 2019 in FDA Updates, Multiple Myeloma, In the News
Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma
Chase Doyle
Web Exclusives published on August 1, 2019 in Multiple Myeloma
HOPA Encourages Oncology Pharmacists to Deliver Patient Outreach Services
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on June 6, 2019 in HOPA
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on June 6, 2019 in Breast Cancer, HOPA
Role of Pharmacists in the Management of Chemotherapy-Induced Nausea and Vomiting
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on June 6, 2019 in Side-Effects Management, HOPA
Last modified: April 27, 2020